


FOR THE AT-RISK ACUTE CORONARY SYNDROME PATIENT:

THE ERA OF TRIPLE ANTIPLATELET THERAPY



Saturday, August 29, 2009
14h30 - 16h00



ESC Congress 2009
Damascus - Zone 1
Barcelona, Spain

Pre-Register online
<http://cme.cybersessions.com/tripleRx/>

Chair

Michael Gibson, MD

Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Co-Chair

Christian Hamm, MD

Professor of Cardiology
Kerckhoff Heart Center
Bad Nauheim, Germany

Faculty

Jean-Pierre Bassand, MD



C.H.U. Jean Minjot
Service de Cardiologie de Besançon
Pôle cœur-poumons
Bd Fleming
Besançon, France

Arnoud van't Hof, MD, PhD

Department of Cardiology
Isala Klinieken
Zwolle, The Netherlands

Neal Uren, MD

Department of Cardiology
Royal Infirmary
Edinburg, United Kingdom



Pre-Register online
<http://cme.cybersessions.com/tripleRx/>

Agenda

14:30 – 14:40	Introductions and introductory remarks <i>Michael Gibson, MD</i>
14:40 – 14:55	Antiplatelet Therapy in ACS: Unmet Needs <i>Christian Hamm, MD</i>
14:55 – 15:15	Current Guidelines for Antiplatelet Therapy in ACS <i>Jean-Pierre Bassand, MD</i>
15:15 – 15:35	Triple Antiplatelet Therapy in STEMI <i>Arnoud van't Hof, MD, PHD</i>
15:35 – 15:55	Triple Antiplatelet Therapy in NSTEMI <i>Neal Uren, MD</i>
15:55 – 16:00	Concluding remarks <i>Michael Gibson, MD</i>

PURPOSE

Thrombosis-associated major adverse cardiac events occur in patients presenting with acute coronary syndromes (ACS) despite treatment with dual antiplatelet regimens. This Satellite Symposium has been designed to present the current literature to define the extent of, and potential reasons for, excess thrombotic events and to discuss when, and in whom, triple antiplatelet therapy is warranted. Presentations from recognized authorities in this field will be interspersed with discussion from a distinguished panel and questions from the audience.

TARGET AUDIENCE

Intended for interventional cardiologists, cardiologists, and allied health professionals involved in the care of patients with at-risk ACS.

LEARNING OBJECTIVES

Following this activity, attendees will be able to:

- Define the unmet needs in antiplatelet therapy for patients presenting with ACS
- Review the current treatment practice guidelines for antiplatelet therapy in ACS
- Discuss triple antiplatelet therapy with aspirin/thienopyridines/glycoprotein IIb/IIIa platelet inhibitors in the setting of ST elevation myocardial infarction
- Describe the use of triple antiplatelet therapy in the setting of non-ST elevation myocardial infarction

ACCREDITATION STATEMENT

This program has been reviewed by the Faculty of Pharmaceutical Medicine and approved for CPD.



This satellite symposium is supported by an independent educational grant from Iroko.